Hereditary Pheochromocytoma Assessment of Tumour Immunologies
HEPHESTOS - Hereditary Pheochromocytoma Assessment of Tumour Immunologies
Radboud University Medical Center
200 participants
Jun 1, 2024
OBSERVATIONAL
Conditions
Summary
In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with and without a hereditary predisposition. The investigators also want to see how the immune system changes during the development of the tumor in people with a hereditary predisposition. Finally, the investigators will compare the data with a control group of people without these tumors. Ultimately, the investigators hope that the results will contribute to the discovery of new immune system-targeted medications for pheochromocytoma and paraganglioma.
Eligibility
Inclusion Criteria7
- Part I:
- Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence.
- OR patients with mutations which predispose for the development of PPGL.
- Aged > 18 years.
- Part II:
- Confirmed PPGL on pathology.
- Aged > 18 years.
Exclusion Criteria6
- Unable to provide informed consent.
- Active inflammatory or infectious comorbidities.
- Other malignancies which are under active treatment (except for basal cell carcinoma, other in situ carcinomas).
- Using medication interfering with the immune system
- Pregnancy or breastfeeding
- A self-reported alcohol consumption of >21 units per week
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood draw in the context of routine patient care, when a venipuncture is already scheduled.
Volunteering for blood draw.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06444607